Pharmavene, Shire Pharmaceuticals Group PLC deal

SHP plans to acquire Pharmavene for £55.5 million ($90.5 million) in cash and stock, including $25 million in cash and $65.5

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE